COVID-19 Therapeutic Options Under Investigation
Copyright © 2020 Kaddoura, AlIbrahim, Hijazi, Soudani, Audi, Alkalamouni, Haddad, Eid and Zaraket..
Since its emergence in China in December 2019, COVID-19 has quickly spread around the globe causing a pandemic. Vaccination or the development of herd immunity seems the only way to slow down the spread of the virus; however, both are not achievable in the near future. Therefore, effective treatments to mitigate the burden of this pandemic and reduce mortality rates are urgently needed. Preclinical and clinical studies of potential antiviral and immunomodulatory compounds and molecules to identify safe and efficacious therapeutics for COVID-19 are ongoing. Two compounds, remdesivir, and dexamethasone have been so far shown to reduce COVID-19-associated death. Here, we provide a review of the potential therapeutic agents being considered for the treatment and management of COVID-19 patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Frontiers in pharmacology - 11(2020) vom: 01., Seite 1196 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kaddoura, Malak [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adjunctive therapy |
|---|
| Anmerkungen: |
Date Revised 12.11.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3389/fphar.2020.01196 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM314220879 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM314220879 | ||
| 003 | DE-627 | ||
| 005 | 20231225152251.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fphar.2020.01196 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1047.xml |
| 035 | |a (DE-627)NLM314220879 | ||
| 035 | |a (NLM)32848795 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kaddoura, Malak |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 Therapeutic Options Under Investigation |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 12.11.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2020 Kaddoura, AlIbrahim, Hijazi, Soudani, Audi, Alkalamouni, Haddad, Eid and Zaraket. | ||
| 520 | |a Since its emergence in China in December 2019, COVID-19 has quickly spread around the globe causing a pandemic. Vaccination or the development of herd immunity seems the only way to slow down the spread of the virus; however, both are not achievable in the near future. Therefore, effective treatments to mitigate the burden of this pandemic and reduce mortality rates are urgently needed. Preclinical and clinical studies of potential antiviral and immunomodulatory compounds and molecules to identify safe and efficacious therapeutics for COVID-19 are ongoing. Two compounds, remdesivir, and dexamethasone have been so far shown to reduce COVID-19-associated death. Here, we provide a review of the potential therapeutic agents being considered for the treatment and management of COVID-19 patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a adjunctive therapy | |
| 650 | 4 | |a antivirals | |
| 650 | 4 | |a therapeutics | |
| 700 | 1 | |a AlIbrahim, Malak |e verfasserin |4 aut | |
| 700 | 1 | |a Hijazi, Ghina |e verfasserin |4 aut | |
| 700 | 1 | |a Soudani, Nadia |e verfasserin |4 aut | |
| 700 | 1 | |a Audi, Amani |e verfasserin |4 aut | |
| 700 | 1 | |a Alkalamouni, Habib |e verfasserin |4 aut | |
| 700 | 1 | |a Haddad, Salame |e verfasserin |4 aut | |
| 700 | 1 | |a Eid, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Zaraket, Hassan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in pharmacology |d 2010 |g 11(2020) vom: 01., Seite 1196 |w (DE-627)NLM208568891 |x 1663-9812 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2020 |g day:01 |g pages:1196 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fphar.2020.01196 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2020 |b 01 |h 1196 | ||